DE2332663C2 - Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie - Google Patents

Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie

Info

Publication number
DE2332663C2
DE2332663C2 DE2332663A DE2332663A DE2332663C2 DE 2332663 C2 DE2332663 C2 DE 2332663C2 DE 2332663 A DE2332663 A DE 2332663A DE 2332663 A DE2332663 A DE 2332663A DE 2332663 C2 DE2332663 C2 DE 2332663C2
Authority
DE
Germany
Prior art keywords
methyl
pregnadiene
dioxo
acid
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2332663A
Other languages
German (de)
English (en)
Other versions
DE2332663A1 (de
Inventor
Peter Dr. Fuchs
Erich Prof. Gerhards
Heinz Dr. Matthes
Hans Wendt
Rudolf Prof. 1000 Berlin Wiechert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to DE2332663A priority Critical patent/DE2332663C2/de
Priority to SE7408091A priority patent/SE7408091L/
Priority to IE1292/74A priority patent/IE39516B1/xx
Priority to ES427480A priority patent/ES427480A1/es
Priority to BE145751A priority patent/BE816709A/xx
Priority to ZA00744022A priority patent/ZA744022B/xx
Priority to IL45087A priority patent/IL45087A/xx
Priority to NLAANVRAGE7408421,A priority patent/NL184724C/xx
Priority to DD179417A priority patent/DD112437A5/xx
Priority to JP49072169A priority patent/JPS6245846B2/ja
Priority to FR7421859A priority patent/FR2233987B1/fr
Priority to DK337574A priority patent/DK337574A/da
Priority to AU70421/74A priority patent/AU493830B2/en
Priority to GB27902/74A priority patent/GB1479488A/en
Publication of DE2332663A1 publication Critical patent/DE2332663A1/de
Priority to US05/714,668 priority patent/US4039668A/en
Application granted granted Critical
Publication of DE2332663C2 publication Critical patent/DE2332663C2/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE2332663A 1973-06-23 1973-06-23 Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie Expired DE2332663C2 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DE2332663A DE2332663C2 (de) 1973-06-23 1973-06-23 Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie
SE7408091A SE7408091L (sk) 1973-06-23 1974-06-19
IE1292/74A IE39516B1 (en) 1973-06-23 1974-06-20 Corticoid-containing inhalant preparations
ES427480A ES427480A1 (es) 1973-06-23 1974-06-20 Procedimiento para la preparacion de un agente de inhala- cion que contiene corticoides.
ZA00744022A ZA744022B (en) 1973-06-23 1974-06-21 Corticoid-containing inhalant preparations corticoid-containing inhalant preparations
IL45087A IL45087A (en) 1973-06-23 1974-06-21 Inhalant preparations containing 3,20-dioxo-pregn-4-enoic acid derivatives
NLAANVRAGE7408421,A NL184724C (nl) 1973-06-23 1974-06-21 Werkwijze voor het bereiden van een farmaceutisch preparaat dat een corticoide bevat.
BE145751A BE816709A (fr) 1973-06-23 1974-06-21 Produits pour inhalation
DD179417A DD112437A5 (sk) 1973-06-23 1974-06-24
JP49072169A JPS6245846B2 (sk) 1973-06-23 1974-06-24
FR7421859A FR2233987B1 (sk) 1973-06-23 1974-06-24
DK337574A DK337574A (sk) 1973-06-23 1974-06-24
AU70421/74A AU493830B2 (en) 1974-06-24 Corticoid-containing inhalant preparations
GB27902/74A GB1479488A (en) 1973-06-23 1974-06-24 Corticoid-containing inhalant preparations
US05/714,668 US4039668A (en) 1973-06-23 1976-08-16 Corticoid-containing inhalants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2332663A DE2332663C2 (de) 1973-06-23 1973-06-23 Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie

Publications (2)

Publication Number Publication Date
DE2332663A1 DE2332663A1 (de) 1975-01-16
DE2332663C2 true DE2332663C2 (de) 1986-07-31

Family

ID=5885228

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2332663A Expired DE2332663C2 (de) 1973-06-23 1973-06-23 Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie

Country Status (13)

Country Link
JP (1) JPS6245846B2 (sk)
BE (1) BE816709A (sk)
DD (1) DD112437A5 (sk)
DE (1) DE2332663C2 (sk)
DK (1) DK337574A (sk)
ES (1) ES427480A1 (sk)
FR (1) FR2233987B1 (sk)
GB (1) GB1479488A (sk)
IE (1) IE39516B1 (sk)
IL (1) IL45087A (sk)
NL (1) NL184724C (sk)
SE (1) SE7408091L (sk)
ZA (1) ZA744022B (sk)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX3864E (es) * 1975-05-27 1981-08-26 Syntex Corp Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
DE2829953A1 (de) * 1978-07-03 1980-01-24 Schering Ag Pharmazeutische zubereitung zur behandlung der kolitis ulcerosa und kolitis granulomatosa
US5215979A (en) * 1985-12-19 1993-06-01 Aktiebolaget Draco 16,17-acetalsubstituted pregnane 21-oic acid derivatives
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB799902A (en) * 1954-08-11 1958-08-13 Merck & Co Inc Therapeutic preparations
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1381872A (en) * 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
BE787100A (fr) * 1971-08-06 1973-02-02 Beecham Group Ltd Composition pour le traitement de l'asthme
GB1387911A (en) * 1971-10-04 1975-03-19 Schering Ag Pregnane acid derivatives
DE2150268C3 (de) * 1971-10-04 1980-11-06 Schering Ag, 1000 Berlin Und 4619 Bergkamen Pregnansäure-Derivate, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
DE2264003C2 (de) * 1972-12-22 1982-11-04 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue Pregnansäure-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
DE2319479C2 (de) * 1973-04-14 1982-10-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Pregnansäure-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
AU7042174A (en) 1976-01-08
DE2332663A1 (de) 1975-01-16
SE7408091L (sk) 1974-12-23
NL7408421A (sk) 1974-12-30
ES427480A1 (es) 1976-07-16
GB1479488A (en) 1977-07-13
NL184724B (nl) 1989-05-16
FR2233987A1 (sk) 1975-01-17
BE816709A (fr) 1974-12-23
IE39516B1 (en) 1978-10-25
DD112437A5 (sk) 1975-04-12
FR2233987B1 (sk) 1977-07-08
JPS6245846B2 (sk) 1987-09-29
ZA744022B (en) 1975-06-25
IE39516L (en) 1974-12-23
JPS5047967A (sk) 1975-04-28
DK337574A (sk) 1975-03-17
IL45087A (en) 1978-04-30
NL184724C (nl) 1989-10-16
IL45087A0 (en) 1974-09-10

Similar Documents

Publication Publication Date Title
DE2332484C2 (de) Arzneimittel mit verzögerter Wirkstoffabgabe
DE69721766T2 (de) Neue arzneiformulierung
EP2723344B1 (de) Monoterpenhaltiges kombinationstherapeutikum
DE2332663C2 (de) Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie
DE2353797A1 (de) Stabilisierung von prostaglandinen
CA2094424C (en) Method of treating osteoporosis with 1.alpha.,24(r)-dihydroxy-22(e)-dehydro-vitamin d3
EP0571457B1 (de) Iloprost mit wirkung gegen cerebrale malaria
DE3619426A1 (de) Mittel zur erhoehung der widerstandskraft gegen erkaeltungskrankheiten bei patienten mit eingeschraenkter lungenfunktion
DE2715384C3 (de) Arzneimittel gegen Diarrhöen
Obase et al. Efficacy and safety of long-term treatment of asthmatic patients with pranlukast, a cysteinyl-leukotriene-receptor antagonist: four-year followup study
EP0509042B1 (de) Intravenös applizierbare Pharmazeutische Zubereitung von 1-Octadecyl-2-methyl-glycero3-phosphocholin
DE2243776A1 (de) Komplexe von tetracyclinen mit tris(hydroxymethyl)-aminomethan
DE2342460A1 (de) Eisen- oder aluminiumglycyrrhizinat enthaltendes produkt, verfahren zu seiner herstellung und dieses produkt enthaltendes arzneimittel
EP0100516A2 (de) 3-Beta-(3'-(Carboxypropionyloxy))-ursa-9(11),12-dien-28-carbonsäure sowie ihre Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US4039668A (en) Corticoid-containing inhalants
EP0340540B1 (de) Mittel zur Prophylaxe des Herzinfarkts und zur Verhütung des Reinfarkts
WO1997038724A1 (de) Neue indikationen für die verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren als arzneimittel
DE2161588C3 (de) Mittel zur Behandlung von Hyperlipoproteinämien
EP0043548A1 (de) Salz aus Furosemid oder Piretanid als Säurekomponente und Penbutolol als Basenkomponente sowie Arzneimittel, das beide Komponenten enthält
DE2401453A1 (de) Pharmazeutische zusammensetzung zur behandlung von hautproliferationserkrankungen
DE10238161A1 (de) Mineralstoff-Ampulle für die mucosale und topische Wirkstoffapplikation
EP0461218B1 (de) Zubereitung eines salzes von oxypurinol in oraler form zur behandlung von hyperuricämie
AT408610B (de) Zusammensetzung aus pflanzenextrakten, insbesondere zur verwendung bei der krebstherapie
DE2714342C2 (de) Bis(acetylsalicylsäure)-thiaalkandiol-ester und therapeutische Zusammensetzung
DE3147959A1 (de) Pharmazeutische zusammensetzung, die 1- 2-(3'-caroxypropionyl)oxyethyl -2-methyl-5-nitroimidazol als therapeutischen wirkstoff gegen erkrankungen enthaelt, die von anaeroben bakterien verursacht sind

Legal Events

Date Code Title Description
OD Request for examination
D2 Grant after examination
8364 No opposition during term of opposition